Profile data is unavailable for this security.
About the company
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. Its segments include Prescription, Over the counter (OTC), Injectables, Active Pharmaceutical Ingredients (API), Finished Dose Form (FDF) and Heparin. It offers sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Its key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables). Its OTC segment includes products that do not require prescriptions and are primarily sold in the retail pharmacy and fast-moving consumer goods sectors. Its Prescription segment includes products which generally require a prescription from a healthcare professional.
- Revenue in ZAR (TTM)42.70bn
- Net income in ZAR4.87bn
- Incorporated1985
- Employees8.61k
- LocationAspen Pharmacare Holdings LtdAspen Place, 9 Rydall Vale ParkDouglas Saunders Drive ,La Lucia RidgeDURBAN South AfricaZAF
- Phone+27 315808600
- Fax+27 112396111
- Websitehttp://www.aspenpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspen Pharmacare Holdings Limited | 42.70bn | 4.87bn | 97.82bn | 8.61k | 20.00 | 1.14 | 15.60 | 2.29 | 10.96 | 10.96 | 96.12 | 192.69 | 0.3286 | 1.28 | 3.33 | 4,958,198.00 | 3.75 | 3.54 | 4.42 | 4.44 | 45.15 | 48.72 | 11.40 | 11.58 | 1.09 | 6.50 | 0.2967 | 19.47 | 5.45 | 1.22 | -19.42 | -1.44 | 1.00 | 1.66 |
| Teva Pharmaceutical Industries Ltd | 302.96bn | -10.69bn | 284.51bn | 35.00k | -- | 1.96 | 27.81 | 0.9391 | -1.89 | -1.89 | 53.42 | 25.33 | 0.3622 | 2.00 | 4.46 | 1,712,768.00 | -1.41 | -3.14 | -1.98 | -4.29 | 50.33 | 48.14 | -3.90 | -9.87 | 0.6911 | 3.55 | 0.7094 | -- | 6.17 | -3.42 | 77.15 | -- | -4.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Public Investment Corporation (SOC) Ltd.as of 02 Feb 2024 | 90.00m | 20.17% |
| Coronation Asset Management (Pty) Ltd.as of 30 Jun 2023 | 24.55m | 5.50% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 15.05m | 3.37% |
| Foord Asset Management Pty Ltd.as of 30 Jun 2023 | 10.78m | 2.42% |
| Schroder Investment Management Ltd.as of 29 Feb 2024 | 7.73m | 1.73% |
| Old Mutual Customised Solutions (Pty) Ltd.as of 30 Jun 2023 | 6.54m | 1.47% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 6.48m | 1.45% |
| GIC Pte Ltd. (Investment Management)as of 30 Jun 2023 | 5.95m | 1.33% |
| Old Mutual Life Assurance Co. (South Africa) Ltd.as of 30 Jun 2023 | 5.09m | 1.14% |
| SAFE Investment Co. Ltd.as of 30 Jun 2023 | 5.09m | 1.14% |
